Drug therapy for alcohol dependence

New England Journal of Medicine

Volumn 340, Issue 19, 1999, Pages 1482-1490

  Swift, Robert M ^a,b  

^a BROWN UNIVERSITY   (United States)

^b PROVIDENCE VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYBUTYRIC ACID; ACAMPROSATE; BROMOCRIPTINE; BUSPIRONE; CALCIUM CARBIMIDE; CARBAMAZEPINE; DISULFIRAM; NALMEFENE; NALTREXONE; TIAPRIDE;

ALCOHOL METABOLISM; ALCOHOL WITHDRAWAL; ALCOHOLISM; DRUG EFFECT; HUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING;

ALCOHOL DETERRENTS; ALCOHOLISM; ANTIDEPRESSIVE AGENTS; DOPAMINE ANTAGONISTS; ETHANOL; HUMANS; MENTAL DISORDERS; NARCOTIC ANTAGONISTS; RECEPTORS, NEUROTRANSMITTER;

EID: 0003276205     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199905133401907     Document Type: Review

References (99)

1. Morse RM, Flavin DK. Definition of alcoholism. JAMA 1992;268: 1012-4.
2. Diagnostic and statistical manual of mental disorders, 4th ed.: DSM-IV. Washington, D.C.: American Psychiatric Association, 1994.
3. McGinnis JM, Foege WH. Actual causes of death in the United States. JAMA 1993;270:2207-12.
4. Rice DP. The economic cost of alcohol abuse and alcohol dependence: 1990. Alcohol Health Res World 1993;17:10-1.
5. Finney JW, Hahn AC, Moos RH. The effectiveness of inpatient and outpatient treatment for alcohol abuse: the need to focus on mediators and moderators of setting effects. Addiction 1996;91:1773-96, 1803-20.
6. Broadening the base of treatment for alcohol problems: report of a study by a committee of the Institute of Medicine, Division of Mental Health and Behavioral Medicine. Washington, D.C.: National Academy Press, 1990.
7. Litten RZ, Allen J, Fertig J. Pharmacotherapies for alcohol problems: a review of research with focus on developments since 1991. Alcohol Clin Exp Res 1996;20:859-76.
8. Chick J, Erickson CK. Conference summary: Consensus Conference on Alcohol Dependence and the Role of Pharmacotherapy in Its Treatment. Alcohol Clin Exp Res 1996;20:391-402.
9. Koob GF, Weiss F. Neuropharmacology of cocaine and ethanol dependence. Recent Dev Alcohol 1992;10:201-33.
10. Samson HH, Hodge CW. The role of the mesoaccumbens dopamine system in ethanol reinforcement: studies using the techniques of microin jection and voltammetry. Alcohol Alcohol Suppl 1993;2:469-74.
11. Wise RA, Bozarth MA. A psychomotor stimulant theory of addiction. Psychol Rev 1987;94:469-92.
12. Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev 1993; 18:247-91.
13. Schuckit MA. Alcohol sensitivity and dependence. EXS 1994;71:341-8.
14. Littleton J, Little H. Current concepts of ethanol dependence. Addiction 1994;89:1397-412.
15. Suzdak PD, Schwartz RD, Skolnick P, Paul SM. Ethanol stimulates gamma-aminobutyric acid receptor-mediated chloride transport in rat brain synaptoneurosomes. Proc Natl Acad Sci U S A 1986;83:4071-5.
16. Hoffman PL, Rabe CS, Grant KA, Valverius P, Hudspith M, Tabakoff B. Ethanol and the NMDA receptor. Alcohol 1990;7:229-31.
17. Linnoila M. NIH conference: alcohol withdrawal and noradrenergic function. Ann Intern Med 1987;107:875-89.
18. Anton RF, Moak DH, Latham PK. The Obsessive Compulsive Drinking Scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behavior. Alcohol Clin Exp Res 1995;19:92-9.
19. Rohsenow DJ, Monti PM, Abrams DB, et al. Cue elicited urge to drink and salivation in alcoholics: relationship to individual differences. Adv Behav Res Ther 1992;14:195-210.
20. Anton RF, Moak DH, Latham PK. The Obsessive Compulsive Drinking Scale: a new method of assessing outcome in alcoholism treatment studies. Arch Gen Psychiatry 1996;53:225-31. [Erratum, Arch Gen Psychiatry 1995;53:576.]
21. Khantzian EJ. The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. Am J Psychiatry 1985;142:1259-64.
22. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990;264:2511-8.
23. Peachey JE, Annis H. Effectiveness of aversion therapy using disulfiram and related compounds. In: Crow KE, Batt RD, eds. Human metabolism of alcohol. Vol. 1. Pharmacokinctics, medicolegal aspects, and general interests. Boca Raton, Fla.: CRC Press, 1989:157-69.
24. Hughes JC, Cook CCH. The efficacy of disulfiram: a review of outcome studies. Addiction 1997;92:381-95.
25. Fuller RK, Branchey L, Brightwell DR, et al. Disulfiram treatment of alcoholism: a Veterans Administration cooperative study. JAMA 1986;256: 1449-55.
26. Chick J, Gough K, Falkowski W, et al. Disulfiram treatment of alcoholism. Br J Psychiatry 1992;161:84-9.
27. Peachey JE, Annis HM, Bornstein ER, Sykora K, Maglana SM, Shamai S. Calcium carbimide in alcoholism treatment. 1. A placebo-controlled, double-blind clinical trial of short-term efficacy. Br J Addict 1989;84:877-87.
28. Hubbell CL, Czirr SA, Hunter GA, Beaman CM, LeCann NC, Reid LD. Consumption of ethanol solution is potentiated by morphine and attenuated by naloxone persistently across repeated daily administrations. Alcohol 1986;3:39-54.
29. Frochlich JC, Harts J, Lumeng L, Li TK. Naloxone attenuates voluntary ethanol intake in rats selectively bred for high ethanol preference. Pharmacol Biochem Behav 1990;35:385-90.
30. Gessa GL, Muntoni F, Collu M, Vargiu L, Mereu G. Low doses of ethanol activate dopaminergic neurons in the ventral tegmental area. Brain Res 1985;348:201-3.
31. Benjamin D, Grant E, Pohorecky LA. Naltrexone reverses ethanol-induced dopamine release in the nucleus accumbens in awake, freely moving rats. Brain Res 1993;621:137-40.
32. Swift RM, Whelihan W, Kuznetsov O, Buongiorno G, Hsuing H. Naltrexone-induced alterations in human ethanol intoxication. Am J Psychiatry 1994;151:1463-7.
33. Volpicelli JR, Watson NT, King AC, Sherman CE, O'Brien CP. Effect of naltrexone on alcohol "high" in alcoholics. Am J Psychiatry 1995;152: 613-5.
34. Monti PM, Rohsenow DJ, Swift RM, Abrams DB, Colby SM, Mueller TI. Effect of naltrexone on urge to drink during alcohol cue exposure: preliminary results. Alcohol Clin Exp Res (in press), abstract.
35. Davidson D, Swift RM, Fitz E. Naltrexone increases the latency to drink alcohol in social drinkers. Alcohol Clin Exp Res 1996;20:732-9.
36. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992;49:876-80.
37. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry 1992;49:881-7.
38. Jaffe AJ, Rounsaville B, Chang G, Schottenfeld RS, Meyer RE, O'Malley SS. Naltrexone, relapse prevention, and supportive therapy with alcoholics: an analysis of patient treatment matching. J Consult Clin Psychol 1996;64:1044-53.
39. McCaul ME, Wand GS, Sullivan J, Mumford G, Quigley J. Betanaltrexol level predicts alcohol relapse. Alcohol Clin Exp Res (in press). abstract.
40. Chick J. UK multicentre study of naltrexone as adjunctive therapy in the treatment of alcoholism: efficacy results. Presented at the 10th World Psychiatry Conference, Madrid, Spain, August 24, 1996.
41. Hersh D, Van Kirk JR, Kranzler HR. Naltrexone treatment of comorbid alcohol and cocaine use disorders. Psychopharmacology (Berl) 1998; 139:44-52.
42. Volpicelli JR, Rhines KC, Rhines JS, Volpicelli LA, Alterman AI, O'Brien CP. Naltrexonc and alcohol dependence: role of subject compliance. Arch Gen Psychiatry 1997;54:737-42.
43. Croop RS, Faulkner EB, Labriola DF. The safety profile of naltrexone in the treatment of alcoholism: results from a multicenter usage study. Arch Gen Psychiatry 1997;54:1130-5.
44. Berg BJ, Pettinati HM, Volpicelli JR. A risk-benefit assessment of naltrexone in the treatment of alcohol dependence. Drug Saf 1997;15:274-82.
45. Naltrexone and alcoholism treatment. Treatment improvement protocol (TIP) series 28. Rockville, Md.: Center for Substance Abuse Treatment, 1998. (DHHS publication no. (SMA) 98-3206.)
46. Salvato FR, Mason BJ. Changes in transaminases over the course of a 12-week, double-blind nalmefene trial in a 38-year-old female subject. Alcohol Clin Exp Res 1994;18:1187-9.
47. Mason BJ, Ritvo EC, Morgan RO, et al. A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcohol Clin Exp Res 1994;18:1162-7.
48. Daoust M, Legrand E, Gewiss M, et al. Acamprosate modulates synaptosomal GABA transmission in chronically alcoholised rats. Pharmacol Biochem Behav 1992;41:669-74.
49. Zeise ML, Kasparov S, Capogna M, Zieglgansberger W. Acamprosate (calciumacetylhomotaurinate) decreases postsynaptic potentials in the rat neocortex: possible involvement of excitatory amino acid receptors. Eur J Pharmacol 1993;231:47-52.
50. Nie Z, Madamba SG, Siggins GR. Ethanol inhibits glutamatergic neurotransmission in nucleus accumbens neurons by multiple mechanisms. J Pharmacol Exp Ther 1994;271:1566-73.
51. Samson HH, Harris RA. Neurobiology of alcohol abuse. Trends Pharmacol Sci 1992;13:206-11.
52. Tsai G, Gastfriend DR, Coyle JT. The glutamatergic basis of human alcoholism. Am J Psychiatry 1995;152:332-40.
53. Littleton J. Acamprosate in alcohol dependence: how does it work? Addiction 1995;90:1179-88.
54. Nalpas B, Dabadie H, Parot P, Paccalin J. L'acamprosate: de la pharmacologie à la clinique. Encephale 1990;16:175-9.
55. Spanagel R, Holter SM, Allingham K, Landgraf R, Zieglgansberger W. Acamprosate and alcohol. I. Effects on alcohol intake following alcohol deprivation in the rat. Eur J Pharmacol 1996;305:39-44.
56. Whitworth AB, Fischer F, Lesch OM, et al. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 1996;347:1438-42.
57. Lhuintre JP, Moore N, Tran G, et al. Acamprosate appears to decrease alcohol intake in weaned alcoholics. Alcohol Alcohol 1990;25:613-22.
58. Ladewig D, Knecht T, Leher P, Fendl A. Acamprosatein - Stabilisierungs faktor in der Langzeitentwöhnung von Alkoholabhängigen. Ther Umsch 1993;50:182-8.
59. Soyka M, Sass H. Acamprosate: a new pharmacotherapeutic approach to relapse prevention in alcoholism - preliminary data. Alcohol Alcohol Suppl 1994;2:531-6.
60. Sass H, Soyka M, Mann K, Zieglgansberger W. Relapse prevention by acamprosate: results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry 1996;53:673-80. [Erratum, Arch Gen Psychiatry 1996;53:1097]
61. Geerings PJ, Ansoms C, van der Brink W. Acamprosate and prevention of relapse in alcoholics: results of a randomized, placebo-controlled, double-blind study in outpatient alcoholics in the Netherlands, Belgium and Luxembourg. Eur Addict Res 1997;3:129-37.
62. Poldrugo F. Acamprosate treatment in a long-term community-based alcohol rehabilitation programme. Addiction 1997;92:1537-46.
63. Chick J. Acamprosate as an aid in the treatment of alcoholism. Alcohol Alcohol 1995;30:785-7
64. Broadbent JG, Grahame NJ, Cunningham CL. Haloperidol prevents ethanol stimulated locomotor activity but fails to block sensitization. Psychopharmacology 1995;120:475-82.
65. George SR, Fan T, Ng GYK, Jung SY, O'Dowd BF, Naranjo CA. Low endogenous dopamine function in brain predisposes to high alcohol preference and consumption: reversal by increasing synaptic dopamine. J Pharmacol Exp Ther 1995;273:373-9.
66. Peters DH, Faulds D. Tiapride: a review of its pharmacology and therapeutic potential in the management of the alcohol dependence syndrome. Drugs 1994;47:1010-32.
67. Shaw GK, Waller S, Majumdar SK, Alberts JL, Latham CJ, Dunn G. Tiapride in the prevention of relapse in recently detoxified alcoholics. Br J Psychiatry 1994;165:515-23.
68. 2 dopamine receptor A1 allele. Nat Med 1995;1:337-41.
69. Naranjo CA, Dongier M, Bremner KE. Long-acting injectable bromocriptine does not reduce relapse in alcoholics. Addiction 1997;92:969-78.
70. Judd LL, Hubbard BR, Huey LY, Attewell PA, Janowsky DS, Takahashi KI. Lithium carbonate and ethanol induced "highs" in normal subjects. Arch Gen Psychiatry 1977;34:463-7.
71. Dorus W, Ostrow DG, Anton R, et al. Lithium treatment of depressed and nondepressed alcoholics. JAMA 1989;262:1646-52.
72. Lejoyeux M, Ades J. Evaluation of lithium treatment in alcoholism. Alcohol Alcohol 1993;28:273-9.
73. Malcolm R, Ballenger JC, Sturgis ET, Anton R. Double blind controlled trial comparing carbamazepine to oxazepam treatment of alcohol withdrawal. Am J Psychiatry 1989;146:617-21.
74. Mueller TI, Stout RL, Rudden S, et al. A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence. Alcohol Clin Exp Res 1997;21:86-92.
75. Ciraulo DA, Sands BF, Shader RI. Critical review of liability for benzodiazepine abuse among alcoholics. Am J Psychiatry 1988;145:1501-6.
76. Gallimberti L, Ferri M, Ferrara SD, Fadda F, Gessa GL. Gammahydroxybutyric acid in the treatment of alcohol dependence: a double-blind study. Alcohol Clin Exp Res 1992;16:673-6.
77. Linnoila M, Eckardt M, Durcan M, Lister R, Martin P. Interactions of serotonin with ethanol: clinical and animal studies. Psychopharmacol Bull 1987;23:452-7
78. Sellers EM, Higgins GA, Sobell MB. 5-HT and alcohol abuse. Trends Pharmacol Sci 1992;13:69-75.
79. LeMarquand D, Pihl RO, Benkelfat C. Serotonin and alcohol intake, abuse, and dependence: findings of animal studies. Biol Psychiatry 1994; 36:395-421.
80. Kranzler HR, Anton RF. Implications of recent neuropsychopharmacologic research for understanding the etiology and development of alcoholism. J Consult Clin Psychol 1994;62:1116-26.
81. Naranjo CA, Sellers EM, Sullivan JT, Woodley DV, Kadlec K, Sykora K. The serotonin uptake inhibitor citalopram attenuates ethanol intake. Clin Pharmacol Ther 1987;41:266-74.
82. Naranjo CA, Poulos CX, Bremner KE, Lanctot KL. Fluoxetinc attenuates alcohol intake and desire to drink. Int Clin Psychopharmacol 1994; 9:163-72.
83. Naranjo CA, Bremner KE. Serotonin altering medications and desire, consumption and effects of alcohol-treatment implications. EXS 1994;71: 209-19.
84. Gorelick DA. Recent developments in alcoholism: pharmacological treatment. Recent Dev Alcohol 1993;11:413-27.
85. Kranzler HR, Burleson JA, Korner P, et al. Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. Am J Psychiatry 1995;152:391-7.
86. Collins DM, Myers RD. Buspirone attenuates volitional alcohol intake in the chronically drinking monkey. Alcohol 1987;4:49-56.
87. Knapp DJ, Pohorecky LA. Zacopride, a 5HT3 receptor antagonist, reduces voluntary ethanol consumption in rats. Pharmacol Biochem Behav 1992;41:847-50.
88. Bruno F. Buspirone in the treatment of alcoholic patients. Psychopathology 1989;22:Suppl 1:49-59.
89. Malec E, Make T, Gagne MA, Dongier M. Buspirone in the treatment of alcohol dependence: a placebo-controlled trial. Alcohol Clin Exp Res 1996;20:307-12.
90. Johnson BA, Jasinski DR, Galloway GP, et al. Ritanserin in the treatment of alcohol dependence - a multi-center clinical trial: Ritanserin Study Group. Psychopharmacology (Berl) 1996;128:206-15.
91. Sellers EM, Toneatto T, Romach MK, Somer GR, Sobell LC, Sobell MB. Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. Alcohol Clin Exp Res 1994;18:879-85.
92. Helzer JE, Pryzbeck TR. The co-occurrence of alcoholism with other psychiatric disorders in the general population and its impact on treatment. J Stud Alcohol 1988;49:219-24.
93. Kessler RC, Crum RM, Warner LA, Nelson CB, Schulenberg J, Anthony JC. Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Arch Gen Psychiatry 1997;54:313-21.
94. Mason BJ, Kocsis JH, Ritvo EC, Cutler RB. A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression. JAMA 1996;275:761-7.
95. McGrath PJ, Nunes EV, Stewart JW, et al. Imipramine treatment of alcoholics with major depression: a placebo-controlled clinical trial. Arch Gen Psychiatry 1996;53:232-40.
96. Cornelius JR, Salloum IM, Ehler JG, et al. Fluoxetine in depressed alcoholics: a double-blind, placebo-controlled trial. Arch Gen Psychiatry 1997;54:700-5.
97. Kranzler HR, Burleson JA, Del Boca FK, et al. Buspirone treatment of anxious alcoholics: a placebo-controlled trial. Arch Gen Psychiatry 1994; 51:720-31.
98. Malcolm R, Anton RF, Randall CL, Johnston A, Brady K, Thevos A. A placebo-controlled trial of buspirone in anxious inpatient alcoholics. Alcohol Clin Exp Res 1992;16:1007-13.
99. Mason BJ. Dosing issues in the pharmacotherapy of alcoholism. Alcohol Clin Exp Res 1996;20:Suppl:10A-16A.